Morozovskaya Children's Municipal Clinical Hospital of the Moscow City Health Department, Moscow, Russia.
Department of Children Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Ital J Pediatr. 2024 Jan 4;50(1):1. doi: 10.1186/s13052-023-01569-7.
Even though the incidence of Multisystem Inflammatory Syndrome in children (MIS-C) is decreasing cases are still reported across the world. Studying the consequences of MIS-C enhances our understanding of the disease's prognosis. The objective of this study was to assess short- and medium-term clinical outcomes of MIS-C.
Prospective observational cohort study at Municipal Children's Hospital Morozovskaya, Moscow, Russia. All children meeting the Royal College of Paediatrics and Child Health (RCPCH), Centers for Disease Control and Prevention (CDC), or the World Health Organization (WHO) MIS-C case definition admitted to the hospital between 17 May and 26 October 2020 were included in the study. All survivors were invited to attend a clinic at 2 and 6 weeks after hospital discharge.
37 children median age 6 years (interquartile range [IQR] 3.3-9.4), 59.5% (22/37) boys were included in the study. 48.6% (18/37) of patients required ICU care. One child died. All children had increased levels of systemic inflammatory markers during the acute event. Echocardiographic investigations identified abnormal findings in 35.1% (13/37) of children. 5.6% (2/36) of children were presenting with any symptoms six weeks after discharge. By six weeks the inflammatory markers were within the reference norms in all children. The echocardiographic evaluation showed persistent coronary dilatation in one child.
Despite the severity of their acute MIS-C, the majority of children in our cohort fully recovered with none having elevated laboratory markers of inflammation at 6 weeks, few (< 10%) reporting persistent symptoms at 6 weeks, and only one with persistent echocardiographic abnormalities.
尽管儿童多系统炎症综合征（MIS-C）的发病率正在下降，但世界各地仍有病例报告。研究 MIS-C 的后果可以增强我们对该疾病预后的理解。本研究的目的是评估 MIS-C 的短期和中期临床结局。
这是一项在俄罗斯莫斯科莫罗佐夫斯基市儿童医院进行的前瞻性观察队列研究。所有符合英国皇家儿科学会和儿童健康学院（RCPCH）、美国疾病控制和预防中心（CDC）或世界卫生组织（WHO）MIS-C 病例定义的，于 2020 年 5 月 17 日至 10 月 26 日期间住院的患儿均被纳入研究。所有幸存者均被邀请在出院后 2 周和 6 周时到诊所就诊。
共纳入 37 例患儿，中位年龄为 6 岁（四分位距 [IQR]：3.3-9.4），59.5%（22/37）为男性。48.6%（18/37）的患儿需要入住重症监护病房。1 例患儿死亡。所有患儿在急性发病期间均有全身性炎症标志物水平升高。超声心动图检查发现 35.1%（13/37）的患儿存在异常。出院后 6 周时，5.6%（2/36）的患儿出现任何症状。在 6 周时，所有患儿的炎症标志物均在参考范围内。超声心动图评估显示，1 例患儿存在持续性冠状动脉扩张。
尽管患儿急性 MIS-C 病情严重，但本队列中的大多数患儿完全康复，在 6 周时无炎症标志物升高，在 6 周时报告持续症状的患儿不到 10%（2/36），仅有 1 例患儿存在持续性超声心动图异常。
